These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33552993)

  • 21. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
    Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
    [No Abstract]   [Full Text] [Related]  

  • 22. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy beyond progression in patients with advanced non-small cell lung cancer.
    Ge X; Zhang Z; Zhang S; Yuan F; Zhang F; Yan X; Han X; Ma J; Wang L; Tao H; Li X; Zhi X; Huang Z; Hofman P; Prelaj A; Banna GL; Mutti L; Hu Y; Wang J
    Transl Lung Cancer Res; 2020 Dec; 9(6):2391-2400. PubMed ID: 33489801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater.
    Jodai T; Saruwatari K; Ikeda T; Moriyama E; Kashiwabara K; Shingu N; Iyonaga K; Inaba M; Ajishi Y; Honda C; Hirosako S; Maruyama H; Kakiuchi Y; Eida H; Tomita Y; Saeki S; Ichiyasu H; Sakagami T
    Int J Clin Oncol; 2021 Jan; 26(1):78-86. PubMed ID: 32965577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression.
    Pourmir I; Elaidi R; Maaradji Z; De Saint Basile H; Ung M; Ismaili M; Fournier L; Rance B; Gibault L; Ben Dhiab R; Gazeau B; Fabre E
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.
    Wang Z; Ying J; Xu J; Yuan P; Duan J; Bai H; Guo C; Li L; Yang Z; Wan R; Fei K; Zhao Z; Du X; Zhao J; Lv N; Wang J
    JAMA Netw Open; 2020 Oct; 3(10):e2013770. PubMed ID: 33017026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer.
    Yang Y; Yang J; Shen L; Chen J; Xia L; Ni B; Ge L; Wang Y; Lu S
    Am J Transl Res; 2021; 13(2):743-756. PubMed ID: 33594323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.
    Soyano AE; Dholaria B; Marin-Acevedo JA; Diehl N; Hodge D; Luo Y; Manochakian R; Chumsri S; Adjei A; Knutson KL; Lou Y
    J Immunother Cancer; 2018 Nov; 6(1):129. PubMed ID: 30470260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
    Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y
    Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor.
    He LN; Chen T; Fu S; Jiang Y; Zhang X; Chen C; Du W; Luo L; Li A; Wang Y; Yu H; Zhou Y; Wang Y; Yang Y; Huang Y; Zhao H; Fang W; Zhang L; Hong S
    Ther Adv Med Oncol; 2023; 15():17588359231200463. PubMed ID: 37881238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Jiang T; Bai Y; Zhou F; Li W; Gao G; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2019 Apr; 130():76-83. PubMed ID: 30885355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan.
    Lin SY; Yang CY; Liao BC; Ho CC; Liao WY; Chen KY; Tsai TH; Hsu CL; Hsu WH; Su KY; Chang YL; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    J Cancer; 2018; 9(10):1813-1820. PubMed ID: 29805708
    [No Abstract]   [Full Text] [Related]  

  • 34. Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab.
    Banna GL; Signorelli D; Metro G; Galetta D; De Toma A; Cantale O; Banini M; Friedlaender A; Pizzutillo P; Garassino MC; Addeo A
    Transl Lung Cancer Res; 2020 Aug; 9(4):1533-1542. PubMed ID: 32953525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
    Goodman AM; Kato S; Bazhenova L; Patel SP; Frampton GM; Miller V; Stephens PJ; Daniels GA; Kurzrock R
    Mol Cancer Ther; 2017 Nov; 16(11):2598-2608. PubMed ID: 28835386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
    Hui R; Garon EB; Goldman JW; Leighl NB; Hellmann MD; Patnaik A; Gandhi L; Eder JP; Ahn MJ; Horn L; Felip E; Carcereny E; Rangwala R; Lubiniecki GM; Zhang J; Emancipator K; Roach C; Rizvi NA
    Ann Oncol; 2017 Apr; 28(4):874-881. PubMed ID: 28168303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-
    Bai X; Dai J; Li C; Cui C; Mao L; Wei X; Sheng X; Chi Z; Yan X; Tang B; Lian B; Wang X; Zhou L; Li S; Kong Y; Qi Z; Xu H; Duan R; Guo J; Si L
    Front Oncol; 2021; 11():639085. PubMed ID: 34094921
    [No Abstract]   [Full Text] [Related]  

  • 38.
    Polverari G; Ceci F; Bertaglia V; Reale ML; Rampado O; Gallio E; Passera R; Liberini V; Scapoli P; Arena V; Racca M; Veltri A; Novello S; Deandreis D
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32380754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases.
    Wang H; Liu F; Chen X; Zhao C; Li X; Zhou C; Hu J; Chu Q; Jiang T
    Exp Hematol Oncol; 2023 Jun; 12(1):56. PubMed ID: 37353805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution.
    He X; Zhang Y; Ma Y; Zhou T; Zhang J; Hong S; Sheng J; Zhang Z; Yang Y; Huang Y; Zhang L; Zhao H
    Medicine (Baltimore); 2016 Aug; 95(31):e4176. PubMed ID: 27495021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.